Sight Sciences, Inc. (SGHT)
- Previous Close
5.13 - Open
5.09 - Bid 5.31 x 100
- Ask 5.47 x 100
- Day's Range
5.09 - 5.44 - 52 Week Range
1.04 - 11.20 - Volume
279,472 - Avg. Volume
186,030 - Market Cap (intraday)
266.102M - Beta (5Y Monthly) 2.83
- PE Ratio (TTM)
-- - EPS (TTM)
-1.14 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.63
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
www.sightsciences.comRecent News: SGHT
Performance Overview: SGHT
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SGHT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SGHT
Valuation Measures
Market Cap
265.61M
Enterprise Value
162.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.22
Price/Book (mrq)
2.21
Enterprise Value/Revenue
2.01
Enterprise Value/EBITDA
-3.30
Financial Highlights
Profitability and Income Statement
Profit Margin
-68.53%
Return on Assets (ttm)
-18.85%
Return on Equity (ttm)
-39.63%
Revenue (ttm)
81.06M
Net Income Avi to Common (ttm)
-55.55M
Diluted EPS (ttm)
-1.14
Balance Sheet and Cash Flow
Total Cash (mrq)
138.13M
Total Debt/Equity (mrq)
29.46%
Levered Free Cash Flow (ttm)
-31.55M